KNSA Stock Analysis: Buy, Sell, or Hold?
KNSA - Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
$43.92
-0.04 (-0.09%)
▼
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 24, 2026
23d
Get Alerted When KNSA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: KNSA shows positive signals but monitor for confirmation. Market pricing in 4.5% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: KNSA shows positive signals but monitor for confirmation. Market pricing in 4.5% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$75.03
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$46.59
5.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 22.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: KNSA is currently trading at $43.92, which is considered extended relative to its 30-day fair value range of $40.20 to $43.35. From a valuation perspective, the stock is trading at a premium (Forward PE: 25.8) compared to its historical average (22.6). At these levels, the market is pricing in 4.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, KNSA is in a strong uptrend. The price is approaching resistance at $45.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KNSA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $55.00 (+25.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KNSA is in a strong uptrend. The price is approaching resistance at $45.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KNSA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $55.00 (+25.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$40.20 -
$43.35
Company Quality Score
59/100
(HOLD)
Options IV Signal
36th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
64.2%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Options fairly priced (IV 36th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 25.1% below Wall St target ($55.00)
- NEUTRAL: Market pricing in 4.5% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$40.20 -
$43.35
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$3.95
(9.0%)
Support & Resistance Levels
Support Level
$38.04
Resistance Level
$45.00
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
25.78
Wall Street Target
$55.00
(+25.1%)
Revenue Growth (YoY)
61.2%
Earnings Growth (YoY)
550.0%
Profit Margin
6.0%
Valuation Premium vs History
+4.5% premium
PE vs Historical
25.8 vs 22.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.5%
(market-implied from PE analysis)
1-Year Target
$45.94
(+5%)
2-Year Target
$48.01
(+9%)
3-Year Target
$50.17
(+14%)
3-Yr Target (if PE normalizes)
(PE: 26→23)
PE COMPRESSION
$43.97
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 25.8, Growth: 53.7%)
$148.36
(+238%)
Base:
(SPY PE: 22.3, Growth: 53.7%)
$128.32
(+192%)
Bear:
(PE: 19.0, Growth: 53.7%)
$109.07
(+148%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (33x PE), but valuation improves significantly next year (26x PE) as earnings recover.
Forward PE: 33.11 | Forward EPS (Implied): $1.33
Bull Case
$53.03
(+21%)
Analyst growth 15.0%, PE expands to 34.8
Base Case
$43.92
(0%)
Market implied 0.0%, PE stable at 33.1
Bear Case
$33.60
(-24%)
Severe decline -15.0%, PE contracts to 29.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: January 31, 2026 5:57 AM ET
Data refreshes hourly during market hours. Next update: 6:57 AM
Data refreshes hourly during market hours. Next update: 6:57 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KNSA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
18
Sells
Net
INSIDERS SELLING
Recent Transactions
Sanj K Patel
SELL
97390 shares
2025-10-22
Sanj K Patel
SELL
39331 shares
2025-10-21
Michael R Megna
SELL
50490 shares
2025-10-20
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$179 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$158 | 56 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$84 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 57 HOLD |
Advanced KNSA Option Strategies
Professional options setups generated by AI based on today's KNSA price and gamma walls.
